Advertisement

The Indian Journal of Pediatrics

, Volume 86, Issue 8, pp 732–739 | Cite as

Monitoring Treatment of Childhood Tuberculosis and the Role of Therapeutic Drug Monitoring

  • Andrea T. Cruz
  • Jeffrey R. StarkeEmail author
Review Article

Abstract

Most children tolerate the first-line antibiotics used to treat Mycobacterium tuberculosis (TB) very well. The most common adverse effect is gastrointestinal distress unrelated to hepatotoxicity; the latter is seen in less than 1% of children. Despite the infrequency of hepatotoxicity, the potential long-term impact of hepatic insufficiency dictates that all children receiving antimycobacterial therapy should be evaluated periodically by symptom screening and physical examination. Routine measurement of transaminases in previously healthy, asymptomatic children is discouraged, as up to 40% of children will have transient, asymptomatic transaminase elevation that should not alter clinical management; measurement of serum liver enzymes is reserved for children who develop symptoms and those with existing liver disease or taking other potentially hepatotoxic drugs. Caregivers and personnel distributing directly-observed therapy need to be cognizant of potential drug toxicities and have a clear understanding of what to do if a child develops symptoms. There are substantial inter-patient variations in serum antibiotic concentrations when the same milligram per kilogram dose is given to different children of varying ages and sizes, reflecting differences in drug absorption and metabolism. While these variations may not impact the outcome of previously healthy children with mild disease, outcomes for children with human immunodeficiency virus infection or severe disease can be worse if sub-therapeutic drug concentrations are achieved. Therapeutic drug monitoring, wherein serum drug concentrations are used to optimize medication doses, should be considered for children with severe disease or if there is concern about alterations in drug absorption or metabolism.

Keywords

Antiretrovirals (ARVs) Pharmacologic variation Therapeutic drug monitoring (TDM) Tuberculous meningitis 

Notes

Authors' Contributions

Both ATC and JRS contributed to the conception, research and writing of this manuscript. JRS will act as guarantor for this paper.

Compliance with Ethical Standards

Conflict of Interest

Dr. Starke is a member of a Data Safety Monitoring Board for the pediatric studies of Delamanid for Otsuka Pharmaceuticals. There is no overlap with-this manuscript. Dr. Cruz has no Conflict of Interest.

Source of Funding

None.

References

  1. 1.
    World Health Organization. Global Tuberculosis Report: 2018. Geneva: World Health Organization; 2018. Available online at http://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf?ua=1. Accessed 25 November 2018.
  2. 2.
    Horita Y, Alsultan A, Kwara A, et al. Evaluation of the adequacy of WHO revised dosages of the first-line antituberculosis drugs in children with tuberculosis using population pharmacokinetic modeling and simulations. Antimicrob Agents Chemother. 2018;62:e00008–18.CrossRefGoogle Scholar
  3. 3.
    Bekker A, Schaaf HS, Draper HR, et al. Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines. Antimicrob Agents Chemother. 2016;60:2171–9.CrossRefGoogle Scholar
  4. 4.
    Dodd PJ, Yuen CM, Sismanidi C, et al. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health. 2017;5:e898–906.CrossRefGoogle Scholar
  5. 5.
    Li Y, Zhu Y, Zhong Q, et al. Serious adverse reactions from antituberculosis drugs among 599 children hospitalized for tuberculosis. Pediatr Infect Dis J. 2017;36:720–5.CrossRefGoogle Scholar
  6. 6.
    Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011;3:e16.CrossRefGoogle Scholar
  7. 7.
    Chang SH, Nahid P, Eitzman SR. Hepatotoxicity in children receiving isoniazid therapy for tuberculosis infection. J Pediatr Infect Dis Soc. 2014;3:221–7.CrossRefGoogle Scholar
  8. 8.
    Cruz AT, Starke JR. Pediatric tuberculosis. Pediatr Rev. 2010;31:13–25.CrossRefGoogle Scholar
  9. 9.
    Cruz AT, Garcia-Prats AJ, Furin J, Seddon JA. Treatment of multidrug-resistant tuberculosis infection in children. Pediatr Infect Dis J. 2018;37:1061–4.CrossRefGoogle Scholar
  10. 10.
    Sanchez-Albisua I, Vidal ML, Joya-Verde G, et al. Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children. Pediatr Infect Dis J. 1997;16:760–3.CrossRefGoogle Scholar
  11. 11.
    Leeb S, Buxbaum C, Fischler B. Elevated transaminases are common in children on prophylactic treatment for tuberculosis. Acta Paediatr. 2015;104:479–84.CrossRefGoogle Scholar
  12. 12.
    Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: literature review and recommendations. Int J Tuberc Lung Dis. 2006;10:1318–30.Google Scholar
  13. 13.
    World Health Organization. Ethambutol efficacy and toxicity: literature review and recommendations for daily and intermittent dosage in children. Geneva: 2006. Available online at: http://apps.who.int/iris/bitstream/handle/10665/69366/WHO_HTM_TB_2006.365_eng.pdf;jsessionid=0524004F476B8A6010AF93059C007BCE?sequence=1. Accessed 24 October 2018.
  14. 14.
    Thee S, Garcia-Prats AJ, Donald PR, et al. Fluoroquinolones for the treatment of tuberculosis in children. Tuberculosis (Edinb). 2015;95:229–45.CrossRefGoogle Scholar
  15. 15.
    Elmaogullari S, Tepe D, Uçaktürk SA, et al. Prevalence of dyslipidemia and associated factors in obese children and adolescents. J Clin Res Pediatr Endocrinol. 2015;7:228–34.CrossRefGoogle Scholar
  16. 16.
    Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society / Infectious Diseases Society of America / Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2016;64:e1–33.CrossRefGoogle Scholar
  17. 17.
    Gopi M, Seshadri MS. Biphasic effect of rifampicin on bilirubin – a case report. J Clin Diagn Res. 2016;10:14–5.Google Scholar
  18. 18.
    Holla SK, Achappa B, ManibettuRaguram P, et al. Isoniazid-induced pure red cell aplasia. BMJ Case Rep. 2018;.pii:bcr-2018-226134.Google Scholar
  19. 19.
    Lee CH, Lee CJ. Thrombocytopenia – a rare but potentially serious side effect of initial daily and interrupted use of rifampicin. Chest. 1989;96:202–3.CrossRefGoogle Scholar
  20. 20.
    Seddon JA, Thee S, Jacobs K, et al. Hearing loss in children treated for multidrug-resistant tuberculosis. J Inf Secur. 2013;66:320–9.Google Scholar
  21. 21.
    Garfein RS, Liu L, Cuevas-Mota J, et al. Tuberculosis treatment monitoring by video directly observed therapy in 5 health districts, California, USA. Emerg Infect Dis. 2018;24:1806–15.CrossRefGoogle Scholar
  22. 22.
    Reynolds HE, Chrdle A, Egan D, et al. Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir. J Antimicrob Chemother. 2015;70:550–4.CrossRefGoogle Scholar
  23. 23.
    World Health Organization. Management of Tuberculosis and HIV Coinfection: Clinical Protocol for the WHO European Region. Available at: http://www.euro.who.int/__data/assets/pdf_file/0004/78124/E90840_Chapter_4.pdf. Accessed 25 November 2018.
  24. 24.
    Antwi S, Yang H, Enimil A, et al. Pharmacokinetics of the first-line antituberculosis drugs in Ghanaian children with tuberculosis with or without HIV coinfection. Antimicrob Agents Chemother. 2017;61:e01701–16.Google Scholar
  25. 25.
    Kwara A, Enimil A, Gillani FS, et al. Pharmacokinetics of first-line antituberculosis drugs using WHO revised dosage in children with tuberculosis with and without HIV coinfection. J Pediatr Infect Dis Soc. 2015;5:356–65.CrossRefGoogle Scholar
  26. 26.
    American Academy of Pediatrics. Tuberculosis. In: Kimberlin DW, Brady MT, Jackson MA, Long SS, editors. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st Ed. Itasca, IL: American Academy of Pediatrics; 2018:p.829–853.Google Scholar
  27. 27.
    Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74:839–54.CrossRefGoogle Scholar
  28. 28.
    Peloquin C. The role of therapeutic drug monitoring in mycobacterial infections. Microbiol Spectr. 2017;5.  https://doi.org/10.1128/microbiolspec.TNM17-0029-2016.
  29. 29.
    Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than 2 years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother. 2011;55:5560–7.CrossRefGoogle Scholar
  30. 30.
    Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb). 2010;90:279–92.CrossRefGoogle Scholar
  31. 31.
    Nahid P, Dorman SE, Alipaneh N, et al. Official American Thoracic Society / Centers for Disease Control and Prevention / Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63:e147–95.CrossRefGoogle Scholar
  32. 32.
    Lange C, Alghamdi WA, Al-Shaer MH, et al. Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis. J Int Med. 2018;284:163–88.CrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2019

Authors and Affiliations

  1. 1.Department of PediatricsBaylor College of MedicineHoustonUSA

Personalised recommendations